Who Owns Journavx?

Suzetrigine emerged from research into the NaV1.8 sodium channel, a protein found almost exclusively in peripheral pain-sensing neurons and absent from the brain and heart. Blocking it promised pain relief without the central nervous system effects that make opioids addictive and without the cardiovascular risks of NSAIDs.

The scientific path took years because earlier sodium channel blockers were too blunt, hitting channels in the heart and brain along with pain nerves. Vertex's medicinal chemistry program produced a molecule selective enough to hit NaV1.8 alone at therapeutic doses.

Phase 3 trials in acute pain settings, abdominoplasty and bunionectomy surgeries, completed in 2024. The drug met its primary endpoints for pain reduction, though it did not beat a hydrocodone-acetaminophen comparator on some secondary measures, a nuance that tempered launch expectations. The FDA approved Journavx on January 30, 2025, for moderate-to-severe acute pain in adults, and it reached US pharmacies in March 2025.

Launch metrics were strong by new-pain-drug standards. More than 550,000 prescriptions were written and filled through the end of 2025, and by January 2026 more than 200 million Americans had formulary coverage for it through commercial and government payers. First-year revenue reached $59.6 million. Vertex is running a Phase 3 program in peripheral neuropathic pain, including diabetic neuropathy, a far larger chronic indication that holds FDA Breakthrough Therapy designation and represents the product's long-term value driver.